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Summary. Background: Intravascular fibrin clots and extravascular fibrin deposits are often implicated in the progression of liver fibrosis. However, evidence supporting a pathological role of fibrin in hepatic fibrosis is indirect and based largely on studies using anticoagulant drugs that inhibit activation of the coagulation protease thrombin, which has other downstream targets that promote fibrosis. Therefore, the goal of this study was to determine the precise role of fibrin deposits in experimental hepatic fibrosis. Methods: Liver fibrosis was induced in mice expressing mutant fibrinogen insensitive to thrombin-mediated proteolysis (i.e. locked in the monomeric form), termed Fib AEK mice, and factor XIII A 2 subunit-deficient (FXIII À/À ) mice. Female wild-type mice, FXIII À/À mice and homozygous Fib AEK mice were challenged with carbon tetrachloride (CCl 4 ) twice weekly for 4 weeks or 6 weeks (1 mL kg
À1
, intraperitoneal). Results: Hepatic injury and fibrosis induced by CCl 4 challenge were unaffected by FXIII deficiency or inhibition of thrombin-catalyzed fibrin polymer formation (in Fib AEK mice). Surprisingly, hepatic deposition of crosslinked fibrin(ogen) was not reduced in CCl 4 -challenged FXIII À/À mice or Fib AEK mice as compared with wild-type mice. Rather, deposition of crosslinked hepatic fibrin(ogen) following CCl 4 challenge was dramatically reduced in tissue transglutaminase-2 (TGM2)-deficient (TGM2 À/À ) mice.
Introduction
Activation of the blood coagulation cascade is evident in experimental settings of chronic liver injury and fibrosis [1, 2] . This is evidenced by increases in plasma levels of biomarkers indicating generation of the coagulation protease thrombin and deposition of fibrin(ogen) within the liver [3] [4] [5] [6] . Numerous studies over the last several decades support the hypothesis that activation of the coagulation cascade contributes to liver fibrosis. For example, administration of anticoagulant drugs or genetically reducing coagulation cascade activation reduces experimental liver fibrosis in rodents [6] [7] [8] [9] [10] . Mice with a prothrombotic state develop worse liver fibrosis than wild-type mice, and patients with hereditary hypercoagulable states show an increased risk for the development of liver fibrosis [9, [11] [12] [13] [14] . Moreover, in a clinical study seeking to reduce the risk of portal vein thrombosis in patients with cirrhosis, anticoagulation was found to delay hepatic decompensation [15] . One ongoing clinical trial is seeking to confirm and expand on this observation by using rivaroxaban in patients with cirrhosis (NCT02643212). Thus, at present, there is strong experimental and clinical evidence indicating a pathological role for increased coagulation activity in liver fibrosis. Several mechanisms are hypothesized to connect increased coagulation activity to the development of fibrosis, with most involving downstream substrates of the coagulation proteases activated factor Xa (FXa) and thrombin. Activation of receptors for these proteases, namely protease-activated receptor (PAR)-1 and PAR-2, has been shown to drive experimental fibrosis [5, 16, 17] and promote a profibrogenic phenotype in cultured hepatic stellate cells [16, 18] . Another widely accepted hypothesis is that thrombin exacerbates liver fibrosis by catalyzing the formation of intrahepatic fibrin clots, which are components of microthrombi that potentially drive parenchymal extinction [6, 19, 20] . Thrombin catalyzes the conversion of soluble fibrinogen to fibrin monomers, which spontaneously polymerize. Thrombin also converts the inactive transglutaminase factor XIII (FXIII) to its active form (activated FXIII [FXIIIa] ), which then stabilizes and crosslinks the fibrin polymers. Fibrin(ogen) deposits are present in the liver in many experimental settings of hepatic fibrosis [3, 4, 6, 21] . The formation of intrahepatic fibrin deposits by this process is proposed to promote fibrosis through multiple mechanisms, including the formation of a provisional matrix supporting subsequent deposition of collagen by activated hepatic stellate cells (i.e. liver myofibroblasts), and by blocking liver blood flow, causing liver damage and parenchymal extinction [22] . In fact, the formation of fibrin clots is frequently considered to be a primary mechanistic connection between hemostasis and liver disease [22] [23] [24] [25] . Despite this, evidence supporting a role for fibrin in liver fibrosis has been indirect, and largely anchored in the protective effects afforded by anticoagulant drugs, which also inhibit the profibrogenic PAR pathways [6, 26, 27] . Commonly used antibodies do not distinguish between fibrinogen and polymerized fibrin in tissues. Therefore, the term fibrin(ogen) has become convential for implying 'either fibrinogen or fibrinogen-derived proteins', including polymerized fibrin. Ultimately, addressing the specific role of thrombin-mediated fibrin clot formation in liver fibrosis has been challenging because of the multiple cellular targets of thrombin. Indeed, there are currently no published studies definitively documenting a pathological role of thrombincatalyzed fibrin polymer formation in liver fibrosis.
Here, using an established model of liver fibrosis induced by chronic carbon tetrachloride (CCl 4 ) challenge, we document, for the first time, the deposition of high molecular weight, crosslinked fibrin(ogen) tightly colocalized with collagen in the fibrotic liver. Moreover, using mice lacking the FXIII catalytic A 2 subunit, and novel mice expressing a mutant form of fibrinogen that does not polymerize in response to thrombin (Fib AEK mice), we tested the longstanding, but unverified, hypothesis that thrombin-catalyzed fibrin clot formation contributes to the pathogenesis of liver fibrosis.
Materials and methods

Mice
Female mice expressing mutant fibrinogen that does not polymerize in response to thrombin (Fib AEK mice) [28] 4 , under isoflurane anesthesia, the liver was excised and rinsed in phosphate-buffered saline. The left lateral lobe was fixed in 10% neutral-buffered formalin for ⁓ 96 h, and processed for routine histopathological analysis. Small sections of liver from different lobes were snap-frozen in liquid nitrogen and saved for other analyses.
Histopathology and immunohistochemistry
Hepatic fibrosis was quantified with multiple complementary approaches as described previously [32] [33] [34] [35] [36] . Staining of formalin-fixed paraffin-embedded liver sections to assess hepatic fibrosis was performed by the MSU Investigative Histopathology Laboratory, a division of Human Pathology. Briefly, paraffin-embedded livers were sectioned at 5 lm and stained with Gladstone-modified picrosirius red (PSR) to visualize hepatic fibrosis (i.e. collagen deposits) as described previously [37] . Expression of a-smooth muscle actin (aSMA) was detected by immunohistochemical labeling of paraffin-embedded liver tissues as described previously [37] . For quantification of the total area of PSR and aSMA staining, slides were first scanned by use of a Virtual Slide System VS110 (Olympus, Waltham, MA, USA) with a 209 objective, and sample images were then digitally captured from the entire left lateral lobe (Visiopharm, Broomfield, CO, USA) as described previously [32, 33, 37] . The total area of positive staining was calculated in an unbiased fashion from 200 images per slide (captured with a 109 virtual objective) by use of a batch macro and color deconvolution tool in IMAGEJ FIJI [38] .
Collagen type I and fibrin(ogen) were detected by immunofluorescent labeling of frozen liver sections. Briefly, frozen tissues were sectioned at 6 lm and fixed in 4% neutral-buffered formalin for 10 min. Following blocking in 10% normal goat serum, sections were incubated with rabbit antimouse collagen type I (Meridian Life Sciences, Memphis, TN, USA; 1 : 500) or rabbit anti-human fibrinogen (Agilent Life Sciences, Santa Clara, CA, USA; 1 : 2500) antibodies overnight at 4°C. Staining was detected with Alexa Fluor 594-conjugated goat anti-rabbit IgG secondary antibody (Jackson Immunoresearch, West Grove, PA, USA). Slides were scanned by use of a VS110 Virtual Slide System, and the area of positive labeling was quantified in four or five randomly selected images (captured with a 49 virtual objective in OLYVIA software; Olympus) (40 mm 2 of liver tissue) by use of a batch macro and threshold analysis tool in IMAGEJ.
Colocalization of collagen and fibrin(ogen) was detected in frozen liver tissues. Tissues were sectioned at 6 lm, fixed in 4% neutral-buffered formalin for 10 min, and then blocked in 10% horse serum for 1 h at room temperature. Sections were coincubated with sheep anti-human fibrinogen (Bio-Rad, Hercules, CA, USA; 1 : 1000) and rabbit anti-collagen type I (Meridian Life Sciences; 1 : 500) antibodies overnight at 4°C. Staining was detected with highly cross-adsorbed donkey anti-sheep IgG and goat anti-rabbit IgG secondary antibodies conjugated to Alexa Fluor 488 and Alexa Fluor 594, respectively (Jackson Immunoresearch). Fluorescently labeled slides were scanned by use of a VS110 Virtual Slide System with a 209 objective.
RNA isolation, cDNA synthesis, and real-time PCR Total RNA was isolated from snap-frozen liver with TRI Reagent according to the manufacturer's protocol (Molecular Research Center, Cincinnati, OH, USA). One microgram of of total RNA was used to synthesize cDNA with a High Capacity cDNA Reverse Transcription Kit (Life Technologies, Foster City, CA, USA) and a C1000 Thermal Cycler (Bio-Rad). SYBR Green quantitative real-time PCR amplification was performed by use of a CFX Connect thermal cycler (Bio-Rad) with primers purchased from Integrated DNA Technologies (Coralville, IA, USA) and PerfeCTa Sybr Green SuperMix (Quanta Biosciences, Beverly, MA, USA). The expression of each gene was normalized to the geometric mean Ct of individual housekeeping genes, i.e. Hprt and Gapdh, and relative fold change was determined with the DDCt method. The primer sequences used have been previously described [33] .
Detection of intrahepatic high molecular weight (HMW) fibrin(ogen) by automated capillary gel electrophoresis Intrahepatic levels of urea-insoluble (i.e. crosslinked [39, 40] ), HMW fibrin(ogen) were determined as described previously [41] , based on protocols adapted for determining fibrin content in venous thrombi [42] . Briefly, 70 mg of snap-frozen liver was homogenized in lysis buffer (20 Intravascular fibrin clots are formed through a classical pathway initiated by thrombin-catalyzed fibrin polymer formation. Crosslinking of the fibrin polymer by the transglutaminase FXIIIa provides stability, and contributes functionally to both hemostasis and thrombosis [43, 44] . FXIII is a heterodimeric protein comprised of two catalytic A subunits and two regulatory B subunits (A 2 B 2 ). To address the role of FXIIIa in liver fibrosis, we induced liver fibrosis with CCl 4 challenge in mice lacking the catalytic A 2 subunit of FXIII (i.e. FXIII À/À mice) [29] . Chronic CCl 4 challenge caused hepatic stellate cell activation, as indicated by increased expression of aSMA ( Fig. 2A,B ) and increased expression of collagen type I mRNA (Col1a1) (Fig. 2C) . A corresponding increase in collagen deposition was observed in the livers of CCl 4 -challenged wild-type mice, as measured by PSR staining and confirmed by immunofluorescent labeling for collagen type I (Fig. 2D-G CCl 4 -challenged wild-type mice ( Fig. 2A-C) . Moreover, this deficiency did not affect collagen deposition in CCl 4 -challenged mice (Fig. 2D-G mice, which express a mutant fibrinogen that is incapable of forming fibrin polymer in response to thrombin [28] . Hepatic stellate cell activation, marked by increased expression of aSMA and Col1a1, was evident in CCl 4 -challenged wild-type mice (Fig. 3A-C) ; this was reflected by a significant increase in hepatic collagen deposition, as indicated by increased PSR staining and collagen type I deposition in the liver (Fig. 3D-G) . Interestingly, markers of stellate cell activation (e.g. aSMA expression) and collagen deposition were similarly increased in livers of CCl 4 -challenged Fib AEK mice as compared with livers of wild-type mice; however, Col1a1 induction was significantly enhanced in livers of CCl 4 -challenged Fib AEK mice. The results indicate that CCl 4 -induced liver fibrosis occurs independently of thrombin-catalyzed fibrin polymer formation.
Hepatic fibrin(ogen) deposition after chronic CCl 4 challenge is mediated by a mechanism independent of thrombindirected fibrin polymer formation or crosslinking by FXIIIa Thrombin-catalyzed fibrin polymer formation is a widely accepted prerequisite for FXIIIa-dependent crosslinking [45] . Moreover, under physiological conditions, FXIIIa is thought to be the primary transglutaminase that crosslinks fibrin(ogen) [46] . Given the critical role that thrombin and FXIIIa play in traditional intravascular fibrin formation [47] , we anticipated a reduction in hepatic fibrin(ogen) deposition in both FXIII À/À mice and Fib AEK mice. However, to our surprise, hepatic fibrin(ogen) deposition driven by chronic CCl 4 challenge was unaffected by FXIII catalytic A 2 subunit deficiency or by the Fib AEK mutation ( Fig. 4A and 5A , respectively). Even more surprisingly, neither FXIII catalytic A 2 subunit deficiency nor the absence of thrombin-catalyzed fibrin polymer formation (i.e. in Fib AEK mice) significantly affected the levels of crosslinked Fiba and Fibc (Fig. 4B,C and 5B,C, respectively) observed after chronic CCl 4 treatment. Collectively, these results indicate that fibrin(ogen) deposits in the livers of CCl 4 -challenged mice are distinct species from those of traditional intravascular fibrin (i.e. are not mediated by thrombin-mediated polymerization or crosslinking by FXIIIa).
Tissue TGM2 crosslinks fibrin(ogen) in experimental liver fibrosis
To identify the FXIII-independent mechanism of fibrin(ogen) crosslinking, we considered TGM2, which is expressed at high levels in the liver, and catalyzes the formation of hybrid Fiba-Fibc chain crosslinks [48] . However, no previous study has documented TGM2-crosslinked fibrin(ogen) in vivo. We found that TGM2 deficiency caused a near-complete reduction in fibrin(ogen) staining in the livers of CCl 4 -treated mice as compared with those of wild-type mice (Fig. 6A) . Importantly, plasma fibrinogen levels were similar in wild-type and TGM2
À/À mice challenged with CCl 4 (data not shown). As compared with wild-type mice, the levels of HMW crosslinked Fiba tended to be reduced, and Fibc levels were significantly reduced, in CCl 4 -treated TGM2 À/À mice ( Fig. 6B-C) . These results indicate that TGM2 crosslinks fibrinogen in experimental liver fibrosis in a manner consistent with in vivo assembly of crosslinked FibAa-Fibc. Notably, the absence of TGM2 and the associated loss of crosslinked fibrin(ogen) did not impact on the development of hepatocellular injury, as indicated by equivalent serum alanine aminotransferase activity (data not shown). No obvious difference in inflammatory cell accumulation was evident in hematoxylin and eosin-stained liver sections, and inflammatory gene induction was comparable in wild-type and TGM2 À/À mice challenged with CCl 4 (data not shown). Moreover, hepatic stellate cell activation, collagen gene expression and hepatic collagen deposition were similar in wild-type and TGM2 À/À mice challenged with CCl 4 , indicating no impact of TGM2 deficiency on hepatic fibrosis (Fig. 7) .
Discussion
Although it has been proposed that intrahepatic fibrin clots have a pathological function in experimental hepatic fibrosis, evidence supporting this hypothesis is limited. To definitively identify the role of fibrin in liver fibrosis, we used experimental tools that precisely interfere with two distinct steps in traditional intravascular fibrin clot formation (i.e. thrombin-catalyzed fibrin polymerization and FXIIIa-mediated fibrin crosslinking), and discovered that traditional crosslinked fibrin polymers do not contribute to the development of experimental hepatic fibrosis. Moreover, in an equally surprising observation, our results suggest that hepatic fibrin(ogen) accumulation in experimental liver fibrosis is driven by a mechanism seemingly independent from blood coagulation. Collectively, these studies contradict the widely held assumption that the thrombin-fibrinogen pathway contributes to experimental liver fibrosis. The longstanding assumption that fibrin clots contribute to fibrosis has been anchored in studies using anticoagulant drugs. However, inhibition of upstream coagulation activity or thrombin itself blocks both proteolytic cleavage of fibrinogen and activation of other thrombin substrates, and therefore does not specifically implicate fibrin as an upstream mediator of liver fibrosis. Our study is the first to unambiguously test the role of thrombin-mediated fibrin polymer formation in experimental fibrosis by using mice expressing Fib AEK , which cannot form fibrin polymer in response to thrombin. We found that selectively blocking the thrombin-fibrinogen pathway had no effect on liver fibrosis. This is critically important because other thrombin targets, including PARs, are still fully operative in the Fib AEK mice. Strong evidence indicates that liver fibrosis is driven by thrombin-mediated (and FXa-mediated) activation of PARs, which constitute a family of tethered-ligand G-proteincoupled receptors [49, 50] . Thrombin is known to activate PAR-1 [51] , and FXa can activate PAR-2 [52] . PAR-1 and PAR-2 are expressed by hepatic stellate cells, and activation of these receptors drives a myofibroblast-like phenotype in vitro [16, 53] . Importantly, experimental liver fibrosis is reduced in PAR-1-deficient and PAR-2-deficient mice [5, 16, 17, 54] . The discovery that fibrin is dispensable for the development of experimental fibrosis supports the hypothesis that PAR-directed profibrogenic pathways constitute an important mechanism connecting coagulation activity to liver fibrosis. Defining the profibrogenic effects of thrombin-PAR signaling may be particularly Traditional intravascular blood clotting includes thrombin-catalyzed fibrin polymer formation as a prerequisite for crosslinking of fibrin(ogen) in physiological conditions [45] , with FXIIIa serving as the predominant enzyme crosslinking fibrin(ogen) in vivo. It is assumed that fibrin (ogen) accumulates in the fibrotic liver as a traditional fibrin 'clot', formed as a consequence of these molecular steps. However, the standard immunolabeling approaches used to detect fibrin(ogen) deposits do not distinguish between these unique fibrin(ogen) crosslinking modifications. By adapting an approach used for quantification of crosslinked fibrin in venous thrombi [42] , we identified an increase in HMW crosslinked a and c chains of fibrin(ogen) in the fibrotic liver. Notably, fibrin(ogen) crosslinking in the fibrotic liver was independent of thrombin-catalyzed fibrin polymerization. Moreover, we found that FXIII catalytic A 2 subunit deficiency did not significantly reduce fibrin(ogen) crosslinking in the livers of CCl 4 -challenged mice. Collectively, these surprising results indicate that, in experimental liver fibrosis, crosslinked fibrin(ogen) accumulates by a mechanism distinct from that of traditional intravascular fibrin. This result raises the question of whether fibrin(ogen) deposits in the injured liver, which constitute a universal feature of acute and chronic liver toxicity, always represent traditional fibrin. The presence of crosslinked Fiba and Fibc chains in livers of CCl 4 -challenged Fib AEK mice suggested that fibrin(ogen) polymer formation was not required for the mechanism of fibrin(ogen) crosslinking in the chronically injured liver. Notably, soluble fibrinogen is a substrate of TGM2, which can crosslink fibrinogen in the absence of thrombin-mediated polymer formation [48] . Multiple hepatic cell types express TGM2, including hepatocytes and stellate cells [55] . Interestingly, TGM2 crosslinking of fibrin(ogen) also favors the production of Fiba-Fibc hybrid fibrin(ogen) [48, 56] , consistent with the observed pattern of crosslinking in livers of CCl 4 -challenged mice. Importantly, we found that TGM2 crosslinking activity was critical to localize fibrin(ogen) to the injured liver, although the cellular source of the TGM2 essential for this localization is not known. To our knowledge, this result offers the first evidence that fibrin(ogen) is a genuine substrate of TGM2 transglutaminase activity in an in vivo setting, validating the documented in vitro biochemical activity of TGM2. Further supporting a direct, coagulation-independent role of TGM2, coagulation cascade activation was evident in both wild-type and TGM2 À/À mice after acute CCl 4 challenge (data not shown). Both fibrinogen [48] and collagen [57] are substrates of TGM2, and prior studies have indicated TGM2 can crosslink these two proteins together [58] . Indeed, it has been reported that in vitro activation of stellate cells (the primary collagen-producing cells in hepatic fibrosis) causes stellate cells to increase expression of TGM2 [55] . This phenomenon may potentially explain the colocalization of these proteins in the injured liver. This may also explain why interventions that reduce collagen deposition (including anticoagulants) also reduce hepatic fibrin(ogen) deposition, inverting the classical assumption that fibrin drives collagen deposition. In the setting of CCl 4 -induced experimental hepatic fibrosis, intrahepatic fibrin(ogen) deposits do not appear to contribute to disease severity. Indeed, hepatic fibrin (ogen) deposition in CCl 4 -challenged TGM2 À/À mice was dramatically reduced as compared with that in wildtype mice, with no effect on hepatic fibrosis, consistent with previous reports that TGM2 deficiency has no effect on the development or resolution of hepatic fibrosis [59] . Notably, this confirms that the reduction in fibrin(ogen) deposits in livers of CCl 4 -challenged TGM2
À/À mice was not indirectly affected by a reduction in disease severity. Overall, whereas fibrin(ogen) appears to not drive liver fibrosis in this experimental setting, the precise role of fibrin(ogen) in acute and chronic liver injury appears to be related to the stimulus used for injury and the experimental context [33, 41] . How precise changes in fibrin(ogen) structure affect these various functions in the injured liver should be investigated in future studies.
The results presented here redefine the current understanding of the contribution of fibrin polymers to experimental hepatic fibrosis. Using two different, but complementary, genetic approaches, we definitively demonstrate that experimental hepatic fibrosis occurs independently of thrombin-directed fibrin polymer formation and FXIIIa-mediated fibrin(ogen) crosslinking. Furthermore, our studies reveal a novel mechanism whereby deposition of fibrin(ogen) in the chronically injured liver is driven by TGM2-directed fibrin(ogen) crosslinking. Collectively, these studies provide strong experimental evidence that the mechanism connecting coagulation activity to liver fibrosis occurs via a pathway independent of hepatic fibrin(ogen) deposition in the chronically damaged liver, suggesting a need to revisit the dogma that fibrin is central to experimental liver fibrosis. 
